$NOVO.B-DK News
Last published 10mo ago
- 10mo agoNOVO.B-DKNVOLLYFDA approves first GLP-1 pill for obesity from Novo NordiskCNBC
- 11mo agoLLYNOVO.B-DKNVOHealthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli LillyCNBC2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
- 12mo agoNOVO.B-DKLLYNVOPFEHealthy Returns: Novo Nordisk boosts the case for its upcoming obesity pill with additional dataCNBCNovo Nordisk released new data to underscore its pill's safety and effectiveness, while Trump is asked whether private plans could see lower GLP-1 costs.
- 1y agoLLYNOVO.B-DKNVOMillions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo NordiskCNBCMedicare will start covering obesity drugs for the first time, which could open access to millions of seniors and spur more private insurers to follow suit.
- 1y agoMTSRNOVO.B-DKPFENVO+1Healthy Returns: What to know about Pfizer and Novo Nordisk’s bidding war over obesity biotech MetseraCNBCPfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to extending tax credits.
- 1y agoMTSRNOVO.B-DKNVOPFE+1Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior�� to revised Pfizer offerCNBCThe clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in.
- 1y agoMTSRNOVO.B-DKPFENVO+1Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotechCNBCThe suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the weight loss drug market.
- 1y agoLLYNOVO.B-DKHIMSNVO+2Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1sCNBCEli Lilly and Novo Nordisk shares dropped after President Donald Trump said he wants a $150 price tag for GLP-1s.
- 1y agoLLYNOVO.B-DKNVOEli Lilly, Novo Nordisk prepare to face off in the next obesity drug battlegroundCNBCEli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medication: pills.
- 1y agoAAPLNOVO.B-DKLLYNVOHealthy Returns: New FDA rules affect copycat GLP-1s, and Apple adds health tools to its latest WatchCNBCThe FDA took a step to crack down on compounded GLP-1s, but it's not exactly a win for Novo Nordisk and Eli Lilly. Meanwhile,
- 1y agoNOVO.B-DKNVOWegovy-maker Novo Nordisk to cut around 9,000 jobsCNBCNovo Nordisk, which produces Wegovy and Ozempic, said roughly 9,000 roles would be cut, with 5,000 of these reductions expected in Denmark.
- 1y agoNOVO.B-DKNVOLLYHealthy Returns: Novo Nordisk’s head of research and development previews the first-ever obesity pillCNBCNovo Nordisk's Martin Holst Lange preveiwed the company's obesity pill, while OpenAI launches new initiative to speed up scientific discovery.
- 1y agoNOVO.B-DKDenmark slashes 2025 growth forecast amid Novo Nordisk slowdownCNBCDenmark on Friday cut its annual growth forecast to 1.4% from 3%.
- 1y agoNOVO.B-DKNVOLLYNovo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patientsCNBCPatients can pay $499 in cash per month for three dose sizes of Ozempic through the company's direct-to-consumer pharmacy and GoodRx, among other platforms.
- 1y agoNOVO.B-DKLLYNVOAMGNHealthy Returns: New weight loss drug data show Eli Lilly is gaining groundCNBCEli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.
- 1y agoNOVO.B-DKNVOHealthy Returns: Ozempic, Wegovy linked to rare cases of serious eye conditionCNBCNovo Nordisk's drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC's Disruptor 50 List.
- 1y agoNOVO.B-DKNVOLLYNovo Nordisk is betting on a CEO shake-up to regain its weight loss drug edge over Eli LillyCNBCNovo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and navigate other challenges
- 1y agoNOVO.B-DKLLYCVSNVOHealthy Returns: Novo Nordisk’s Wegovy deal with CVS won't derail Eli Lilly's obesity market dominanceCNBCEli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
- 1y agoNOVO.B-DKHIMSNVOHims & Hers brings former Amazon executive into C-suiteCNBCHims & Hers Health announced Nader Kabbani will join the telehealth company as its chief operations officer.
- 1y agoCVSNOVO.B-DKNVOLLYCVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plansCNBCStarting July 1, Caremark will prioritize Wegovy on its formulary, making the weekly injection more accessible to its members.
- 1y agoNOVO.B-DKHIMSNVOLLYNovo Nordisk opens weight loss drug Wegovy to Hims & Hers, Ro and Life MD telehealthCNBCThe drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.
- 1y agoNOVO.B-DKNVOHIMSLLYNovo Nordisk scores major legal win that bars many compounded versions of Wegovy, OzempicCNBCPatients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn't have insurance coverage for the treatments.
- 1y agoNOVO.B-DKLLYNVOTrump drops Biden's proposal for Medicare to cover obesity drugs like Wegovy and ZepboundCNBCThe Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.
- 1y agoNOVO.B-DKNVOLLYNovo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four yearsCNBCThe results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart disease.
- 1y agoLLYNOVO.B-DKNVOPFE+4Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changerCNBCThe trial results are critical, as it brings Eli Lilly's pill one step closer to becoming a new, needle-free alternative for weight loss and diabetes.
- 1y agoNOVO.B-DKDXCMNVOHealthy Returns: Wegovy is linked to an increased risk of hair loss, study suggestsCNBCNovo Nordisk's weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom received a warning letter from FDA.
- 1y agoNOVO.B-DKNVOLLYNovo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacyCNBCThe pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.
- 1y agoNOVO.B-DKNVOHIMSLLYShortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA saysCNBCThe FDA's decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
- 1y agoNOVO.B-DKNVOLLYNovo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugsCNBCOzempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.
- 1y agoNVOLLYNOVO.B-DKHealthy Returns: Why people quit weight loss, diabetes drugs within one yearCNBCA new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to focus on GLP-1 products.
- 1y agoNOVO.B-DKNVOLLYFDA approves Novo Nordisk’s diabetes drug Ozempic for chronic kidney disease, expanding its useCNBCOzempic's expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.
- 1y agoCINOVO.B-DKLLYNVO+1High-cost weight loss drugs are sending employers to nutrition counseling in a boost for startupsCNBCStartup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss management program.
- 1y agoNOVO.B-DKNVOHealthy Returns: Novo Nordisk's Ozempic faces scrutiny over potential link to rare eye conditionCNBCA vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, a new Doximity report finds.
- 1y agoHIMSNVONOVO.B-DKLLY+1The weight-loss drug boom has become one of the internet's biggest scamsCNBCAs demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according to cybersecurity experts.
- 1y agoLLYNOVO.B-DKGDRXNVOPrescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx saysCNBCThe jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
- 1y agoNOVO.B-DKLLYNVOEli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trialCNBCZepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
- 2y agoNOVO.B-DKNVOLLYNovo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA saysCNBCIt is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.
- 2y agoNOVO.B-DKNVOLLYNovo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study saysCNBCThe active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer's diagnosis in diabetes patients.
- 2y agoNOVO.B-DKNVOLLYNovo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copiesCNBCThe Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for those manufacturers to make safely.
- 2y agoNOVO.B-DKOzempic underworld: Inside the black market of obesity drugsCNBCA CNBC investigation into illegal weight loss drugs reveals a marketplace where criminals brazenly counterfeit the drugs or ship the real product from overseas.
- 2y agoNOVO.B-DKNVOLLYNovo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study saysCNBCThe results suggest Ozempic could potentially become a new alternative treatment for opioid use disorder, which could help address the ongoing opioid epidemic.
- 2y agoNOVO.B-DKNVOUNHCVS+1'Stop ripping us off': Senate grills Novo Nordisk CEO on weight loss drug pricingCNBCSen. Bernie Sanders argues that Novo Nordisk charges Americans substantially higher prices for its drugs than it does for patients in other countries.
- 2y agoLLYNOVO.B-DKNVOHealthy Returns: Eli Lilly gains momentum against Novo Nordisk in the weight loss drug marketCNBCEli Lilly may be starting to gain an edge over Novo Nordisk in the GLP-1 market. Meanwhile, Stryker will acquire artificial intelligence startup Care.ai.
- 2y agoLLYNOVO.B-DKEli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soarCNBCThe success of Eli Lilly's weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance.
- 2y agoLLYNOVO.B-DKEli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA saysCNBCDemand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and rival Novo Nordisk to invest billions to ramp up manufacturing.
- 2y agoLLYNOVO.B-DKAUGXVKTX+1Healthy Returns: Here’s what GLP-1s are being tested for beyond weight loss, diabetesCNBCThe list of potential health benefits from GLP-1 is only getting longer. Meanwhile, the heads of Commure, Augmedix share details about an acquisition.
- 2y agoNOVO.B-DKLLYBIIBOlder GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study saysCNBCLiraglutide is sold under the brand names Saxenda and Victoza, and sales are declining as blockbuster GLP-1s Ozempic and Wegovy skyrocket in demand.
- 2y agoLLYVKTXNOVO.B-DKViking Therapeutics stock jumps 16% after drugmaker moves weight loss injection to late-stage trialCNBCIt brings the drugmaker one step closer to joining the market for GLP-1s, which analysts say could grow into a $150 billion market by the end of the decade.
- 2y agoMRKAZN-GBJNJBMY+2Healthy Returns: The first round of Medicare drug price negotiations is nearing an endCNBCThe first round of Biden's Medicare drug price negotiations is nearly finished. Meanwhile, Abridge, Epic and Mayo Clinic are bringing AI tools to nurses.
- 2y agoNOVO.B-DKNovo Nordisk's Wegovy weight loss drug wins UK approval for use as a heart treatmentCNBCThe U.K.'s health regulator on Tuesday approved the use of Novo Nordisk's Wegovy drug to reduce the risk of obese adults suffering from serious heart problems or strokes.